Capricor Therapeutics (NASDAQ:CAPR) CFO Sells 24,100 Shares

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer directly owned 11,223 shares in the company, valued at $340,954.74. This represents a 68.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Anthony Bergmann also recently made the following trade(s):

• On Monday, June 22nd, Anthony Bergmann sold 500 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $15,000.00.
• On Wednesday, June 24th, Anthony Bergmann sold 400 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $12,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.70, for a total value of $792,500.00.

Capricor Therapeutics Stock Down 10.0%

NASDAQ CAPR opened at $23.80 on Tuesday. The company has a market cap of $1.38 billion, a PE ratio of -10.26 and a beta of 0.39. Capricor Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $40.37. The firm’s 50-day simple moving average is $29.79 and its two-hundred day simple moving average is $28.39.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, equities research analysts anticipate that Capricor Therapeutics, Inc. will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds have recently bought and sold shares of CAPR. Creek Drive Management Group LLC purchased a new stake in Capricor Therapeutics in the 4th quarter worth approximately $1,039,000. Moody Aldrich Partners LLC purchased a new position in shares of Capricor Therapeutics during the 4th quarter valued at $6,025,000. Pier Capital LLC grew its position in shares of Capricor Therapeutics by 35.0% during the 3rd quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock valued at $3,580,000 after purchasing an additional 128,837 shares in the last quarter. UBS Group AG increased its holdings in shares of Capricor Therapeutics by 91.0% in the fourth quarter. UBS Group AG now owns 238,216 shares of the biotechnology company’s stock worth $6,875,000 after purchasing an additional 113,499 shares during the period. Finally, HBK Sorce Advisory LLC increased its holdings in shares of Capricor Therapeutics by 19.4% in the fourth quarter. HBK Sorce Advisory LLC now owns 203,705 shares of the biotechnology company’s stock worth $5,879,000 after purchasing an additional 33,128 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CAPR shares. Piper Sandler reissued an “overweight” rating and set a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Roth Mkm reaffirmed a “buy” rating and issued a $38.00 price target on shares of Capricor Therapeutics in a report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. B. Riley Financial lifted their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $53.67.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.